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A cooperative clinical study of photodynamic therapy (PDT) for superficial esophageal
carcinoma was conducted at 6 medical institution. PHE (2mg/kg) with high tumor
affinity was used as the oncotropic compound. The light source was a pulse wave YAG-
OPO laser with high penetration into the tissue. Irradiation was performed at an energy
density of 60-180J/cm
2 48-72h after PHE administration. Eight lesions in 6 patients
were treated. All were type 0-II superficial carcinomas. The depth of invasion was EP-
MM for 6 lesions and SM for 2 lesions. A complete response (CR) was achieved in all
patients after one session of PDT. Five adverse events, including anemia and fever, were
reported by 4 patients, but all were WHO grade 2 or lower and transient. PDT using
PHE and YAG-OPO laser was therefore considered effective as a curative therapy for
superficial esophageal carcinoma.
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INTRODUCTION
Photodynamic therapy (PDT) is performed by
applying laser as excitation light 48-72h after
intravenous injection of a photosensitive com-
pound to destroy tumors selectively using the
difference in concentration between the tumor
and normal tissue. Hayata et al. [1] successfully
used PDT under endoscopic guidance to treat lung
carcinoma, and since then PDT has been applied
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to various types of cancers. Okushima et al. [2]
and Mimura et al. [3] achieved a complete
response with PDT for superficial esophageal
carcinoma. These studies used a continuous-wave
Argon-dye laser. In 1990, an Excimer-dye pulse
laser was developed. Pulse lasers provide superior
penetration of light into tissue and produce the
same results using less energy than continuous
lasers [4,5]. In a phase III clinical study by the
authors, PHE (porfimer sodium) and Excimer-
dye laser were found to be effective in the treat-
ment of superficial esophageal carcinoma [6].
However, there was a need for a compact, easy-
maintenance laser unit that could be tuned
according to the type of photosensitive com-
pound used. This led to the development of a
laser for PDT using an Nd :YAG laser excitation
optical parametric oscillator (YAG-OPO laser).
We report on a clinical study of PDT for super-
ficial esophageal carcinoma using a YAG-OPO
laser and PHE.
exposed to laser. (6) The lesion targeted in the
present study had not been treated previously.
Patients in whom a cancer remained after local
endoscopic therapy other than PDT were consid-
ered eligible. Before commencement of treatment,
written informed consent was obtained from the
patient or a family member.
3. Patient Characteristics (Table I)
Six patients (8 lesions) were enrolled, all of
whom were considered eligible. The mean age
was 67.7 years (41-80 years). Five patients had a
PS of 0 and one had a PS of 1. All lesions were
classified as superficial carcinomas based on tis-
sue type and type 0-II based on endoscopic type.
Two lesions showed SM invasion and the others
were M carcinomas of EP-MM. Two patients
had double lesions, which were considered to be
two separate lesions and were treated separately
with PDT.
MATERIALS AND METHODS
1. Participating Institution and Study Period
The present study was conducted at 6 institutions
on patients enrolled between June 1995 and
December 1996.
2. Subjects
The subjects enrolled in the present study were
patients with superficial esophageal carcinoma
who met the following criteria. (1) A presumptive
diagnosis of superficial esophageal carcinoma
was made by endoscopy and a definitive diagno-
sis was made histologically. (2) Radical therapy
such as surgery was infeasible. (3) There was no
concomitant active carcinoma at any site other
than the esophagus. (4) The tumor measured
3 cm or less along the major axis (or had an area
of 7 cm
2 or less). (5) The whole aspect of the
tumor could be observed endoscopically and
TABLE Patient characteristics
Age Mean 67.7
Sex Male 5 cases
Female
PS 0 5 cases
Site Ce lesion
Im 6
Ei
Tissue type Wel. dif. SCC 2 lesion
Mod. dif. SCC 6
Macroscopic classification 0-IIb 3 lesion
0-IIc 5
Tumor size (major and minor axis cm2)
1.0 2 lesion
1.1-2.0 2
2.1-4.0 2
4.1- 2
Depth of invasion EP-MM 6 lesion
SM 2
PS: performance status; Ce: cervical esophagus; Im: middle
thoracic esophagus; Ei: lower thoracic esophagus; EP: intra-
epithelium; MM: up to the level of muscularis mucosae; SM:
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4. Administration of Agents
PHE (porfimer sodium) is a photosensitive com-
pound (Lederle Japan, containing dihematopor-
phyrin ester/ether as an active ingredient). PHE
2.0 mg/kg was injected intravenously.
RESULTS
1. Antitumor Efficacy (Table II, Fig. 1)
All lesions showed CR after one session of PDT,
giving a CR rate of 100%.
5. Laser Irradiation
The laser used in this present study was YAG-OPO
laser (Ishikawajima-Harima Heavy Industries Co.,
Ltd, model iLS-TL-50A). The unit reconverts the
wavelengths of a third harmonic generation of
355nm wavelength converted from the Q-switched
Nd:YAG laser of 1,064nm wavelength with excit-
ing an optical parametric oscillator and has the
following specifications: (a) wavelength range:
620-670 nm, tuned to 630nm in this trial; (b) pulse
rate: 25 and 50 Hz; (c) maximum pulse energy:
6 mJ/pulse; and (d) pulse width: 5-8 ns.
The laser beam was applied to lesions under
direct endoscopic guidance 48-72h after PHE
administration. The irradiation energy density
was generally 60-180 J/cm2.
TABLE II Clinical response
CR PR NC CRrate
8 lesion 0 0 100.0%
CR: complete reaction; PR: partial reaction;
NC: no change.
6. Management of Patients after PHE
Administration
The patients were protected from light after
administration of PHE to prevent development
of photohypersensitivity.
7. Assessment of Efficacy
Endoscopy and histologic biopsy of the lesions
were performed at appropriate intervals after laser
irradiation to assess the direct efficacy ofPDT. As-
sessment was made using the Criteria for Handling
ofEsophageal Carcinoma [7]. But patients inwhom
biopsies remained carcinoma-negative for 4 weeks
or longer were considered complete responders.
8. Assessment of Safety
Safety was assessed using the descriptions of side
effects in the criteria for the assessment of the
efficacy of chemotherapy for solid cancers.
Normal picture pre-treatment
After week
Normal picture after month
Pre-treatment Lugol staining
After 2 weeks
Lugol staining after month
FIGURE Clinical course of PDT (endoscopic picture). (1)
normal picture pre-treatment; (2) pre-treatment Lugol stain-
ing; (3) one week later; (4) two weeks later; (5) normal picture
one month later; (6) Lugol staining one month later.176 K. YOSHIDA et al.
TABLE III Side effects
Side effects Grade Total
2 3 4
Anemia
Renal impairment 2 2
Fever
Abdominal pain
Diarrhea
2. Safety (Table III)
Four of the six patients reported 5 adverse events
thought to be attributable to therapy. All were
mild (Grade 2 or less) and disappeared during
follow-up, except for patient who was given
antipyretics for fever.
DISCUSSION
Surgical intervention is the standard treatment
for esophageal carcinoma, which is often asso-
ciated with lympho-vascular involvement and
lymph node metastasis. However, esophageal car-
cinomas are more common among the elderly
than are other gastrointestinal carcinomas, and
in an increasing number of patients, major sur-
gery such as thoracotomy and laparotomy is
infeasible due to complications. We assessed the
clinical efficacy of PDT using YAG-OPO laser as
local therapy for such inoperable superficial esoph-
ageal carcinomas.
PDT has been reported to be a highly effective
treatment for esophageal carcinoma that is capable
of curing carcinomas up to the SM stage [8]. How-
ever, SM esophageal carcinomas are frequently
associated with lympho-vascular involvement and
lymph node metastasis [9]. M carcinomas of EP-
MM should therefore be treated using local ther-
apy such as PDT. Although endoscopic muco-
sectomy is becoming the standard treatment for
these M carcinomas, PDT has several advantages
in that it is simpler to perform than mucosectomy
and can be used in patients prone to hemorrhage
or with carcinoma complicated by esophageal
varices. Another great advantage of PDT is that
it is aimed at inoperable cases and is therefore
applicable to SM carcinomas.
The local CR rate of 100% obtained in the
present study is higher than the efficacy rates
reported previously [2,3,8] and is superior to the
efficacy of pulse-wave Excimer-dye laser [6,10].
The laser used in the present study is expected to
be highly useful as assessment of safety found no
serious side effects in patients with complicating
illness.
It was concluded from these results that PDT
using the YAG-OPO pulse-wave laser is an effec-
tive local therapy.
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